OR-CIRIUM
3.6.2021 13:02:11 CEST | Business Wire | Press release
Americans are confident to fly again, with 78% of travelers intending to travel for leisure, according to results from a new survey from Cirium , the aviation analytics company. Of those who travel for business, 67% indicate their employer will permit travel in the next three to six months. Some 40% of respondents who intend to return to the skies plan to fly this summer. However, only a small minority had plans to travel by air for major holidays such as the July 4th weekend (16%) and Labor Day weekend (17%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005493/en/
The firm interviewed 2,140 adults across the US between May 11 and 17, 2021, in a nationally representative sample. The margin of error in the reported data did not exceed +/- 3% at the 95% confidence level.
A strong majority of US travelers (90%) intend to fly at some point in the future, and 64% are planning to fly within the next 12 months.
More than three-quarters (78%) of those with plans to travel this year are only planning for domestic trips. Only 22% expect to fly internationally in 2021. The survey also reveals that over one-quarter of respondents reported having taken a flight since the pandemic. Some 60% of respondents indicated that the pandemic will have no impact on their long-term travel plans.
“Cirium’s traveler survey identifies the confidence of the US in flying again, with a majority taking to the skies domestically already—mainly to visit family. The results indicate that the challenges facing US airlines is not lack of travel demand, but on the health and safety measures in place at the airport and in flight,” said Jeremy Bowen, CEO at Cirium.
“US business travel may see some green shoots of recovery in the fall of 2021, as corporations plan to release restrictions on travel.”
While US airlines are increasing domestic flights for summer 2021 and Americans show interest in flying again, travelers expressed health and safety concerns, which impact their travel decisions.
Respondents strongly support the adoption of health passports for future air travel, with 59% supporting a requirement to carry mandatory passes to fly—though 20% disagree with the idea. When asked what airline measures would increase their motivation to fly, the majority of participants identified mandatory mask-wearing (61%) and improved cleaning processes (61%) as the top two measures.
The majority of respondents (78%) identify leisure travel as the main purpose for travel, however the survey reveals optimism for business travel returning in the fall.
Of the respondents who said they travel for business, just 34% were currently permitted to travel by their employer, increasing to 67% within the next three to six months.
The rise in working from home seems to have had little effect on the likelihood to travel for business reasons, as half of US respondents claim there is no change and nearly a quarter (24%) said they are more likely to travel for business.
More than half the respondents reported that they could work remotely and 40% of these respondents claim that the pandemic has increased the chances that they would combine a vacation with work.
Additional insights on air travel in the full report:
- Awareness of new startup airlines in the US
- Long-haul flying on single-aisle aircraft
- Lounge usage and time spent at the airport
- The influence of sustainability concerns on travel
Click here to see the full US Cirium Traveler Intelligence Report.
Complete data with results by age group, US region and gender available on request. Similar data for the UK is available. The survey into traveler sentiment was carried out by independent market intelligence firm AudienceNet on behalf of Cirium.
Ends
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
